TG Therapeutics Inc (TGTX)

Gross profit margin

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Gross profit (ttm)	US$ in thousands	136,219	85,088	178,340	134,391	88,381	63,212	-76,772	-71,239	-67,327	-74,994	-93,703	-114,131	-94,831	-108,508	-110,897	-92,821	-107,698	-68,095	-36,113	-24,395
Revenue (ttm)	US$ in thousands	329,004	262,359	340,582	280,254	222,343	180,883	18,875	6,331	2,784	5,025	6,961	7,912	6,689	4,406	2,414	907	152	152	152	152
Gross profit margin		41.40%	32.43%	52.36%	47.95%	39.75%	34.95%	-406.74%	-1,125.24%	-2,418.35%	-1,492.42%	-1,346.11%	-1,442.51%	-1,417.72%	-2,462.73%	-4,593.91%	-10,233.85%	-70,853.95%	-44,799.34%	-23,758.55%	-16,049.34%

December 31, 2024 calculation

Gross profit margin = Gross profit (ttm) ÷ Revenue (ttm)
= $136,219K ÷ $329,004K
= 41.40%

TG Therapeutics Inc's gross profit margin experienced a significant recovery over the period analyzed. The margin was deeply negative in the first quarters of 2020 and 2021, indicating that the company was incurring significant costs relative to its sales revenue.

However, from the second half of 2021 onwards, there is a clear and consistent improvement in the gross profit margin. The company managed to turn around its profitability, moving from negative margins to positive margins. Notably, by the end of 2024, the gross profit margin reached around 41.40%, indicating that the company was generating gross profit equivalent to 41.40% of its sales revenue.

This positive trend in the gross profit margin suggests that TG Therapeutics Inc successfully implemented strategies to control costs, improve operational efficiencies, or enhance pricing strategies. It also indicates improved profitability and overall financial health of the company.